Drug intelligence / Profile preview

mRNA-4200

Development stage: Phase 1
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

mRNA-4200 is an investigational mRNA-based oncology therapeutic being developed by Moderna. It is designed to encode specific tumor-associated or tumor-specific antigens, leveraging Moderna's mRNA platform to stimulate a targeted anti-tumor immune response. As of 2026, it is in Phase 1 clinical development for the treatment of advanced solid tumors. The drug is being evaluated both as a monotherapy and in combination with the PD-1 inhibitor pembrolizumab to assess safety, tolerability, and preliminary efficacy in patients with advanced malignancies.

Beyond the preview

Go deeper on mRNA-4200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA-4200.

Explore the full profile